| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
66 |
| Employees |
540 |
| Revenues (TTM) (Millions $) |
235 |
| Net Income (TTM) (Millions $) |
-322 |
| Cash Flow (TTM) (Millions $) |
-158 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Global Blood Therapeutics Inc. (GBT) is a biopharmaceutical company that was founded in 2011 with a mission to develop novel therapies for patients who suffer from blood-based disorders. Its headquarters are located in South San Francisco, California, and the company currently employs over 400 people. GBT is focused on the discovery, development, and commercialization of innovative treatments for sickle cell disease (SCD) and other blood disorders.
GBTes flagship drug, Oxbryta (voxelotor), is the first FDA-approved treatment for SCD in over 20 years. The drug works by inhibiting the polymerization of sickle hemoglobin, which reduces the risk of red blood cell sickling and leads to improved blood flow and oxygen delivery. Oxbryta has been shown to improve hemoglobin levels, reduce hemolysis rates, and increase exercise capacity in patients with SCD. The drug has been approved for use in patients aged 12 years and older.
GBT is also developing a pipeline of other drugs for the treatment of SCD, including inclacumab, which is a monoclonal antibody that targets a specific inflammatory mediator in SCD. The company is also researching the potential of gene therapy as a curative treatment for SCD, and has formed partnerships with leading gene therapy companies to advance this work.
In addition to SCD, GBT is exploring treatments for other hemoglobin-based disorders, such as beta-thalassemia. The companyes pipeline includes a drug candidate called GBT440, which has shown promise in reducing hemolysis and improving quality of life in patients with beta-thalassemia.
GBT is committed to developing therapies that improve the lives of patients with blood disorders, and has formed partnerships with patient advocacy organizations, clinicians, and other stakeholders to advance this mission. The company also prioritizes diversity, equity, and inclusion in its workplace and has received recognition for its efforts in this area.
In terms of financials, GBT reported total revenue of $252 million in 2020, largely driven by the launch of Oxbryta. The company is listed on the NASDAQ stock exchange under the ticker symbol GBT.
Company Address: 181 Oyster Point Boulevard South San Francisco 94080 CA
Company Phone Number: 741-7700 Stock Exchange / Ticker: NASDAQ GBT
|
%
20% 